Effect of anakinra on cytokine storm during sepsis-induced multiple organ dysfunction syndrome: case report and preclinical investigation - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Anakinra on Cytokine Storm in Sepsis-Related Multiple Organ Dysfunction Syndrome: A Case Study and Preclinical Analysis

  • By

  • Rebecca M. Blade

  • Sarah P. Lecher

  • Todd M. Umstead

  • Zissis C. Chroneos

  • Cainan Riccio-Baum

  • S. Rameeza Allie

  • Timothy J. Hahn

  • Daniel J. McKeone

  • Jessica E. Ericson

  • Theodore DeMartini

  • Debbie Spear

  • E. Scott Halstead

  • August 19, 2026

Share

Clinical Report: Impact of Anakinra on Cytokine Storm in Sepsis-Related MODS

Background

Sepsis-related MODS is a critical condition characterized by the failure of multiple organ systems due to a dysregulated immune response. Cytokine storms, driven by inflammatory mediators, can exacerbate organ dysfunction and increase mortality.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

  • A 9-year-old female developed sepsis-related MODS following human metapneumovirus infection.
  • Anakinra was administered at a dosage of 100 mg every 12 hours for 8 days, leading to improved organ function.
  • Cytokine analysis showed significant reductions in IL-6 and IL-8 concentrations post-anakinra treatment.
  • Preclinical models suggest IL-6 levels may be influenced by the synergistic actions of IL-1 and TNF.
  • The patient's Pediatric Risk of Mortality III (PRISM III) score indicated a 67% mortality risk.
  • Therapeutic plasma exchange was also utilized to address thrombocytopenia-associated multiple organ failure (TAMOF).

Clinical Implications

Further research is needed to establish optimal treatment protocols, including patient selection and timing of intervention.

Conclusion

Further investigation in clinical settings is warranted.

Related Resources & Content

  1. Frontiers in Pediatrics, 2026 -- Respiratory Effects of Off label Anakinra in Critically Ill Neonates: A 15-Patient Observational Cohort Study
  2. the pathologist, 2024 -- In Other News… Infectious Disease
  3. Frontiers in Immunology, 2026 -- Anakinra for Tocilizumab-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES) with Normal IL-1β Levels: A Case Report
  4. Surviving Sepsis Campaign Adult Guidelines | SCCM
  5. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial | JAMA
  6. Frontiers in Immunology — Integrated multi-omics deciphers sepsis immune dysregulation: a dual-pathway targeted small-molecule therapy improves survival and ameliorates multi-organ dysfunction
  7. Surviving Sepsis Campaign Adult Guidelines | SCCM
  8. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial | Allergy and Clinical Immunology | JAMA | JAMA Network

Original Source(s)

Effect of anakinra on cytokine storm during sepsis-induced multiple organ dysfunction syndrome: case report and preclinical investigation

  • by Rebecca M. Blade, Sarah P. Lecher, Todd M. Umstead, Zissis C. Chroneos, Cainan Riccio-Baum, S. Rameeza Allie, Timothy J. Hahn, Daniel J. McKeone, Jessica E. Ericson, Theodore DeMartini, Debbie Spear, E. Scott Halstead

  • August 19, 2026

Related Content

Author Correction: A multimodal embedding model for sepsis data representation

Does High PCT Warrant Longer Therapy?

In a planned BALANCE analysis, elevated day 7 procalcitonin was associated with higher mortality, but the small subgroup analysis found no evidence that extending antibiotics from 7 to 14 days improved outcomes.

Toll-like receptors in infectious myocarditis: pathogen-specific recognition, spatiotemporal dynamic regulation and clinical translation